Shrank William H, Stedman Margaret, Ettner Susan L, DeLapp Dee, Dirstine June, Brookhart M Alan, Fischer Michael A, Avorn Jerry, Asch Steven M
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA.
J Gen Intern Med. 2007 Sep;22(9):1298-304. doi: 10.1007/s11606-007-0284-3. Epub 2007 Jul 24.
Increased use of generic medications conserves insurer and patient financial resources and may increase patient adherence.
The objective of the study is to evaluate whether physician, patient, pharmacy benefit design, or pharmacy characteristics influence the likelihood that patients will use generic drugs
DESIGN, SETTING, AND PARTICIPANTS: Observational analysis of 2001-2003 pharmacy claims from a large health plan in the Western United States. We evaluated claims for 5,399 patients who filled a new prescription in at least 1 of 5 classes of chronic medications with generic alternatives. We identified patients initiated on generic drugs and those started on branded medications who switched to generic drugs in the subsequent year. We used generalized estimating equations to perform separate analyses assessing the relationship between independent variables and the probability that patients were initiated on or switched to generic drugs.
Of the 5,399 new prescriptions filled, 1,262 (23.4%) were generics. Of those initiated on branded medications, 606 (14.9%) switched to a generic drug in the same class in the subsequent year. After regression adjustment, patients residing in high-income zip codes were more likely to initiate treatment with a generic than patients in low-income regions (RR = 1.29; 95% C.I. 1.04-1.60); medical subspecialists (RR = 0.82; 0.69-0.95) and obstetrician/gynecologists (RR = 0.81; 0.69-0.98) were less likely than generalist physicians to initiate generics. Pharmacy benefit design and pharmacy type were not associated with initiation of generic medications. However, patients were over 2.5 times more likely to switch from branded to generic medications if they were enrolled in 3-tier pharmacy plans (95% C.I. 1.12-6.09), and patients who used mail-order pharmacies were 60% more likely to switch to a generic (95% C.I. 1.18-2.30) after initiating treatment with a branded drug.
Physician and patient factors have an important influence on generic drug initiation, with the patients who live in the poorest zip codes paradoxically receiving generic drugs least often. While tiered pharmacy benefit designs and mail-order pharmacies helped steer patients towards generic medications once the first prescription has been filled, they had little effect on initial prescriptions. Providing patients and physicians with information about generic alternatives may reduce costs and lead to more equitable care.
增加仿制药的使用可节省保险公司和患者的财务资源,并可能提高患者的依从性。
本研究的目的是评估医生、患者、药房福利设计或药房特征是否会影响患者使用仿制药的可能性。
设计、设置和参与者:对美国西部一家大型健康计划2001 - 2003年药房索赔进行观察性分析。我们评估了5399名患者的索赔情况,这些患者至少在5类有仿制药替代的慢性药物中的1类中开具了新处方。我们确定了开始使用仿制药的患者以及那些开始使用品牌药物并在次年改用仿制药的患者。我们使用广义估计方程进行单独分析,评估自变量与患者开始使用或改用仿制药的概率之间的关系。
在开具的5399份新处方中,1262份(23.4%)是仿制药。在开始使用品牌药物的患者中,606名(14.9%)在次年改用了同一类别的仿制药。经过回归调整后,居住在高收入邮政编码地区的患者比低收入地区的患者更有可能开始使用仿制药(风险比 = 1.29;95%置信区间1.04 - 1.60);医学专科医生(风险比 = 0.82;0.69 - 0.95)和妇产科医生(风险比 = 0.81;0.69 - 0.98)比全科医生开始使用仿制药的可能性更小。药房福利设计和药房类型与仿制药的开始使用无关。然而,如果患者参加三层药房计划,他们从品牌药改用仿制药的可能性会高出2.5倍以上(95%置信区间1.12 - 6.09);在开始使用品牌药物治疗后,使用邮购药房的患者改用仿制药的可能性高出60%(95%置信区间1.18 - 2.30)。
医生和患者因素对仿制药的开始使用有重要影响,生活在邮政编码地区最贫困的患者反而最不常使用仿制药。虽然分层药房福利设计和邮购药房在首次处方开具后有助于引导患者使用仿制药,但它们对初始处方影响不大。向患者和医生提供有关仿制药替代品的信息可能会降低成本并带来更公平的医疗服务。